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Abstract
Endothelial dysfunction is a hallmark of a wide range of cardiovascular diseases and is often
linked to oxidative stress and inflammation. Our earlier study reported the formation of a
functional heterodimer between bradykinin receptor 2 (B2R) and dopamine receptor 2
(D2R) that may modulate cell responses, dependent on intracellular signaling. Here, for the
first time, we showed a cooperative effect of these receptors on the modulation of processes
involved in oxidative stress, inflammation, and apoptosis in endothelial cells. Sumanirole, a
specific D2R agonist, was shown to diminish the excessive production of reactive oxygen
species induced by bradykinin, a proinflammatory B2R-activating peptide. This effect was
accompanied by modified activities of antioxidant enzymes and increased phosphorylation
of endothelial nitric oxide synthase, leading to enhance NO production. In turn, endothelial
cell co-stimulation with B2R and D2R agonists inhibited the release of interleukin-6 and
endothelin-1 and modulated the expression of apoptosis markers, such as Bcl-2, Bcl-xL,
Bax, and caspase 3/7 activity. All these observations argue that the D2R agonist counter-
acts the pro-oxidative, pro-inflammatory, and pro-apoptotic effects induced through B2R,
finally markedly improving endothelial functions.
Introduction
Many endothelial dysfunctions are closely associated with oxidative stress generation. A large
body of evidence has indicated that reactive oxygen species (ROS) participate in disorders
such as hypertension, hypercholesterolemia, and atherosclerosis. Enhanced oxidative stress
may impair endothelium-dependent vascular relaxation and induce vascular contractile activ-
ity [1–2]. The importance of oxidative stress in the appearance of chronic heart failure has also
been documented. Rapid production of ROS after heart failure can overwhelm antioxidant
defenses and cause further tissue damage [3]. Moreover, augmented ROS release can lead to
pathological angiogenesis, as observed during cancer progression, by modulation of the vascu-
lar endothelial growth factor production [4]. Therefore, studies involving new antioxidant
mechanisms in the regulation of endothelial dysfunction may be of interest.
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Bradykinin (BK), a nonapeptide rapidly produced and degraded under physiological condi-
tions at vessel walls, plays an essential role in numerous processes occurring in the endothe-
lium [5]. The biological effects of bradykinin are mainly mediated by the bradykinin receptor
type 2 (B2R), which belongs to the large superfamily of G protein-coupled receptors (GPCRs).
B2R activation is particularly important in the regulation of vascular tone and arterial pressure
[5]. However, a high concentration of this peptide can modify various endothelial functions,
e.g., by increasing vascular permeability and inducing angiogenesis [6], i.e. processes that are
accompanied by the release of proinflammatory mediators and strictly correlated with the
development of oxidative stress [7]. The precise role of BK in the regulation of oxidative stress
is still not clear. Numerous studies have suggested that this peptide acts as an antioxidative fac-
tor. Such a protective role of BK is manifested by suppression of ROS production and an
increase in superoxide dismutase (SOD) activity in endothelial progenitor cells as well as in
cardiomyocytes [8–9]. On the other hand, it has also been shown that BK can induce ROS gen-
eration in endothelial cells and vascular smooth muscle cells [10–12]. Furthermore, BK can
increase the release of F2-isoprostane in patients, leading to a strong pro-oxidative response in
the human vasculature [13].
The dopamine receptor type 2 (D2R), another member of the GPCR superfamily, is also
involved in the regulation of the balance between ROS generation and antioxidant systems
[14]. The fact that D2R agonists exert neuroprotective effects by activating antioxidant and
anti-apoptotic processes is well known [15]. It has also been demonstrated that the D2R ago-
nist ropinirole decreases lipid peroxidation and modulates catalase (CAT) and superoxide dis-
mutase activities in the mice striatum [16]. In contrast, injection of the D2R antagonist can
abolish the antioxidant effect of this receptor in the rat brain [17]. The dopamine D2 receptor
is present in several cell types including endothelial cells, in which it regulates diverse func-
tions. The importance of this receptor in down-regulation of von Willebrand factor secretion,
resulting in a reduction of endothelial activation during inflammation, has been reported [18].
In addition, D2R stimulation increases the expression of endogenous antioxidants including
the paraoxonase enzyme, which is responsible for prevention of endothelial cell apoptosis [19].
These findings suggest that D2R agonists may be useful in regulating disorders that involve
endothelium dysfunction.
Lately, there has been growing interest in cooperation between GPCRs, particularly in the
context of their oligomerization, which may be associated with the regulation of physiological
processes through changes in signaling pathways of each receptor [20]. An appreciable number
of interactions of B2R and D2R with other GPCRs to form oligomeric complexes has been
recently reported (for a review see reference [21]). Furthermore, we have reported for the first
time that the formation of a functional heterodimer between B2 and D2 receptors can modu-
late cell responses and that this is dependent on the intracellular Ca2+concentration as well as
on cAMP-dependent pathways [22]. This recent evidence has thus led us to suppose that the
interaction between B2R and D2R can have consequences for the regulation of oxidative and
inflammatory processes in endothelial cells. Hence, we here investigated the influence of BK
and sumanirole (SUM), i.e. specific agonists for the B2 and D2 receptors, respectively, on oxi-
dative stress, inflammatory response, and apoptotic processes in human endothelial cells.
Materials and methods
Chemicals
BK was supplied by Bachem (Bubendorf, Switzerland). Antibiotics, antimycotics, cell culture
medium, and fetal bovine serum (FBS) were purchased from Corning (Corning, NY). All
primers were obtained from Genomed (Warsaw, Poland). Apocynin, bacitracin, captopril,
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4’,6-diamidyno-2-fenyloindol (DAPI), 2,3-diaminonaphthalene, 2,7-dichlorodihydrofluores-
cein diacetate (DCFH-DA), endothelial cell growth supplement, heparin, icatibant (HOE 140),
2-mercaptomethyl-3-guanidinoethylthiopropanoic acid, nitro blue tetrazolium, protease
inhibitors, SUM maleate, S-(−)-eticlopride hydrochloride (eticlopride), and standard chemi-
cals were supplied by Sigma-Aldrich (St Louis, MO). The human tumor necrosis factor alpha
(TNF-α) was purchased from Thermo Fisher Scientific (Waltham, MA).
Antibodies
Mouse monoclonal antibody raised against Bcl-2 (#15071) and rabbit monoclonal antibody
against Bcl-xL (#2764) were obtained from Cell Signaling Technology (Danvers, MA). Rab-
bit polyclonal antibody against the D2 receptor (MBS612859) was purchased from MyBio-
Source (San Diego, CA) and rabbit polyclonal antibody against the B2 receptor (NBP2-
14351) from Novus Biologicals (Littleton, CO). Mouse monoclonal antibodies against β-
actin (MAB8929) and Bax (MAB846) as well as goat polyclonal antibody against mouse or
rabbit IgG conjugated with horseradish peroxidase (HAF007 or HAF008, respectively) were
supplied by R&D Systems (Minneapolis, MN). Mouse monoclonal antibody against endo-
thelial nitric oxide synthase (NOS3) (sc-376751) and against phospho-NOS3 (pNOS3) (sc-
293032) were purchased from Santa Cruz Biotechnology (Dallas, TX). Goat polyclonal anti-
body against rabbit IgG conjugated with Alexa-Fluor488 (A11008) was obtained from
Thermo Fisher Scientific.
Cell culture
The human endothelial cell line (HUV-EC-C; ATCC CRL-1730) purchased from ATCC
(Manassas, VA) was cultured in F-12K medium (Kaighn’s Modification of Ham’s F-12
Medium) supplemented with 10% FBS, 1 U/mL penicillin, 1 μg/mL streptomycin, 2.5 μg/mL
amphotericin B, 50 μg/ml endothelial cell growth supplement, and 100 μg heparin at 37˚C in a
humidified atmosphere containing 5% CO2. Twenty-four hours before each experiments, cells
were cultured in cell medium with 10% FBS without growth factors and all stimulations were
performed in F-12K medium containing 1% FBS.
Gene expression analysis
Total RNA from cells was isolated with ReliaPrep RNA Miniprep Systems (Promega, Madison,
WI) and cDNA was synthesized with an M-MLV Reverse Transcriptase kit (Promega) in
accordance with the manufacturer’s instructions. First, cDNA was synthesized from 500 ng of
total RNA. Next, 2 μl of cDNA was amplified in a 25 μl reaction mixture with PCR Master Mix
2x (Thermo Fisher Scientific) and specific primers using a C1000 Touch Thermal Cycler (Bio-
Rad, Hercules, CA). The primer pair sequences for B2R were 5’-TGCTGCTGCTATTCATCA
TC-3’ (sense) and 5’-CCAGTCCTGCAGTTTGTGAA-3’ (antisense), which are comple-
mentary to template at positions 1020–1039 and 1335–1354, respectively. Whereas primer pair
for D2R were 5’-CTCTTCGGACTCAATAACGCA-3’ (sense) and 5’-CTTTAGTGGAGCC
CTCAGGT-3’ (antisense) which are complementary to template at positions 746–766 and
939–958, respectively. The B2R primers are located in the exon 3 while D2R primers are
located between exons 3 and 4. The PCR conditions were as follows: 95˚C for 10 min followed
by 30 cycles of 95˚C for 15 s, 58˚C for 15 s, and 72˚C for 30 s. The PCR products for B2R and
D2R, resolved on a 2% agarose gel, were 335 and 213 bp in length, respectively.
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Detection of B2 and D2 receptor protein expression by
immunofluorescence
The cell surface expression of B2R and D2R was examined by immunofluorescence micros-
copy using antibodies against external receptor epitopes. Briefly, cells (3 × 105) were seeded
onto glass coverslips in 12-well plates, fixed in 3.7% paraformaldehyde, and incubated in 10%
FBS for one hour. The plates were then incubated overnight with primary antibodies (1:250
dilution) at 4˚C. After washing, the samples were treated for one hour with the secondary anti-
body conjugated with Alexa-Fluor488 (1:250 dilution). Then, 2 μM DAPI was added for 10
minutes and, after extensive washing, the cover slides were mounted on microscope slides
using Fluorescent Mounting Medium (DAKO, Santa Clara, CA). A negative control sample
with no primary antibody incubation was also prepared. The samples were analyzed with an
epifluorescence microscope (Leica DMI6000B, Wetzlar, Germany) at a magnification of 40×
with oil immersion.
ROS measurement
The intracellular ROS level was determined using a fluorometric assay with DCFH-DA dye
[23]. Cells (1 × 105) were seeded onto a microplate precoated with 1% gelatin. After a 24-hour
starvation, the cells were incubated for 30 minutes with 100 μM DCFH-DA in medium con-
taining 1% FBS. After washing, cell stimulation with 100 nM BK, 100 nM SUM, or with both
agonists was performed. The fluorescence signal changes were measured every 30 seconds
over a 20-minute period at 37˚C, using a microplate Synergy H1 reader (BioTek Instruments,
Winooski, VT) at excitation and emission wavelengths of 485 nm and 528 nm, respectively.
Some samples were pretreated with the B2R and D2R antagonists for 30 minutes (10 μM HOE
140 or 10 μM eticlopride, respectively) or for one hour with 1 μM apocynin before dye loading.
The percentage changes in ROS production were presented relative to the untreated cells,
which were assigned a reference value of 100%.
Analysis of the antioxidant enzyme activity
Changes in catalase activity were evaluated by spectrometric measurements of hydrogen per-
oxide decomposition [24]. Endothelial cells (1 × 106) were stimulated with 100 nM BK, 100
nM SUM, or both agonists, and after 2-hour incubation CAT activity in cell lysates was ana-
lyzed using a Hitachi U-2910 spectrophotometer (Tokyo, Japan). In some experiments, cells
were preincubated with 10 μM HOE 140 or eticlopride for 30 minutes before stimulation. In
turn, superoxide dismutase activity was measured with an in-gel activity assay after resolution
of cell lysate proteins by native PAGE. Enzymatic activity was detected by the reduction of
nitro blue tetrazolium in the presence of riboflavin and light [25]. Mitochondrial (MnSOD)
and cytoplasmic (Cu/ZnSOD) superoxide dismutase activities were measured by densitomet-
ric estimation of stained SOD-generated products with Quantity One Software (BioRad, CA,
USA). Changes in CAT an SOD activity were normalized to the total protein level in each sam-
ple, which was determined using the Bradford method.
Measurement of NO release
NO release was measured as described previously [26]. Briefly, cells (4 × 105) were seeded into
a 12-well plate. After achieving 80% confluence and starvation, the cells were treated with 100
nM BK, 100 nM SUM, or both agonists simultaneously for 30 and 60 minutes. After incuba-
tion, supernatant fluorescence was measured using a Synergy H1 microplate reader at the
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excitation and emission wavelengths of 365 nm and 450 nm, respectively. The NO production
was normalized to the amount of sample protein determined by the Lowry method.
Detection of intracellular proteins by western blotting
Cells (1 × 106) were treated with 100 nM BK, 100 nM SUM, or both agonists for 6 and 24
hours for the determination of Bax, Bcl-2, and Bcl-xL protein levels, or for 2 and 5 minutes for
the measurement of endothelial nitric oxide synthase (NOS3) and NOS3 phosphorylated at
Ser1177 (pNOS3). Thereafter, cell lysates were prepared with Laemmli lysis buffer (0.125 M
Tris-HCl, 20% glycerol, 4% SDS, 400 mM dithiothreitol, 0.004% bromophenol blue, pH 6.8)
supplemented with 5 mM sodium fluoride and 1 mM sodium orthovanadate. Equal volumes
of each sample were subjected to SDS-PAGE (polyacrylamide gel electrophoresis) in a 12% gel.
Resolved proteins were transferred to polyvinylidene difluoride membranes (Sigma Aldrich)
in Tris/glycine buffer (25 mM Tris, 192 mM glycine, 20% methanol, pH 8.3) for 1 hour. After
overnight blocking with 5% non-fat milk, the membrane was incubated for 24 hours at 4˚C
with primary antibodies at dilutions of 1:200 for anti-pNOS3 and anti-NOS3, 1:500 for anti-
Bcl-2, 1:1000 for anti-Bax, and 1:2000 for anti-β-actin and anti-Bcl-xL. Next, after extensive
washing, the membrane was incubated with the respective secondary antibody conjugated
with horseradish peroxidase at a 1:1000 dilution. After one-hour incubation and extensive
washing, enzymatic reaction was performed with Immobilon Western Chemiluminescent
HRP Substrate (Sigma-Aldrich) in accordance with the manufacturer’s instructions. β-actin,
as a housekeeping protein, was analyzed in every blot as a normalization control. The bands
was analyzed by densitometric analysis with Quantity One Software.
Measurement of interleukin-6 concentration by ELISA
Confluent cells seeded into a 12-well plate were stimulated for 6 hours with 100 nM BK, 100
nM SUM, or both agonists. Some samples were additionally preincubated with 10 μM HOE
140 or 10 μM eticlopride for 30 minutes prior to receptor agonist induction. All experiments
were performed in cell medium supplemented with protease and kininase inhibitors (10 μM
2-mercaptomethyl-3-guanidinoethylthiopropanoic acid, 20 μM captopril, and 500 μM bacitra-
cin). The interleukin-6 (IL-6) concentration in the medium was evaluated using a specific
ELISA kit (BD Biosciences, Franklin Lakes, NJ) in accordance with the manufacturer’s instruc-
tions and normalized to the amount of sample protein. Absorbance was measured with a
PowerWave microplate reader (BioTek Instruments) at 450 nm. An inflammated cellular
model was established using cells pretreated with the inflammatory mediator TNF-α at a con-
centration of 10 ng/ml for 24 hours before stimulation with agonists.
Caspase 3/7 activity measurements
Caspase 3/7 activity was assayed with a chemiluminescent CaspoGlo3 assay (Promega) using a
luminogenic substrate. Cells (1 × 104) were preincubated or not with 10 ng/ml TNF-α for 6
hours. Next, the cells were stimulated with receptor agonists, as mentioned above, in 1% FBS
cell medium supplemented with kininase inhibitors. After 24 hours, caspase 3/7 activity was
studied according to the manufacturer’s instructions. Chemiluminescence was measured
using a Synergy H1 microplate reader. The obtained values in the samples are presented as
percentage changes in the chemiluminescence signal relative to a control sample (untreated
cells), which was assigned a reference value of 100%.
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Analysis of endothelin-1 production by ELISA
Confluent cells seeded into a 12-well plate were pretreated or not with 10 ng/ml TNF-α for 6
hours and subsequently stimulated for 24 hours with 100 nM BK, 100 nM SUM, or both ago-
nists in cell medium supplemented with kininase inhibitors. The endothelin-1 (ET-1) concen-
tration was determined using an Endothelin-1 Quantikine ELISA kit (R&D Systems).
Absorbance was measured with a PowerWave microplate reader (BioTek Instruments) at 450
nm and the results were normalized to the protein concentration in samples.
Statistical analysis
All data from at least three experiments were expressed as mean values ± SD. For statistical com-
parisons of the mean values in the groups, one-way analysis of variance (ANOVA) was carried
out. To show the difference between the groups Tukey post hock test was used. The analysis was
performed with the statistical environment R using the "stats" library [27]. The full version of
results from the statistical analysis is found in the supporting information (S1 Table).
Results
Endogenous expression of bradykinin B2 and dopamine D2 receptors in
the HUV-EC-C cell line
To evaluate the effect of the B2R and D2R agonists on the generation of oxidative stress in the
endothelial cell line used, we first examined the endogenous expression of both proteins on the
surface of these cells. The presence of the two genes was demonstrated by RT-PCR. The PCR
products obtained for B2R and D2R, resolved using a 2% agarose gel, were 335 bp and 213 bp,
respectively (Fig 1A). In addition, immunocytochemistry studies with specific antibodies
against epitopes on the extracellular domains of B2R or D2R in non-permeabilized cells facili-
tated the detection of these receptors on the cell surface. The resulting images revealed endoge-
nous protein expression of both receptors (green signal) at the cell membrane (Fig 1B).
Negative samples were omitted due to lack of a fluorescence signal.
Effect of B2R and D2R agonists on ROS production
The most commonly used indicator of dysregulated oxidative processes in cells is the ROS
level. In this study, changes in ROS generation by endothelial cells were evaluated after treat-
ment with 100 nM BK, considered to be a pathological concentration [28], and/or with SUM,
a highly selective D2R agonist, at a concentration above to its EC50 value [29].The results were
presented as the percentage of the maximal change in ROS production relative to untreated
cells (with an assigned reference value of 100%) (Fig 2). A significant increase in the ROS level
was observed after treatment with BK and BK+SUM (by 155% and 72%, respectively) in compari-
son to the untreated cells. However, the value achieved in samples stimulated with BK+SUM was
significantly lower compared with the BK-treated cells (by 83%), indicating a strong diminution
of ROS production. Cells incubated with SUM showed no changes in the ROS generation. The
preincubation with the B2R antagonist–HOE 140 –resulted in a reduction in ROS production in
cells activated with BK and BK+SUM (by 128% and 54%, respectively), compared with the corre-
sponding sample without the antagonist treatment. In turn, prestimulation with eticlopride had
no significant effect on the BK action. In this case, the induction of ROS production (by 130%)
was similar to that observed in the BK-stimulated sample without the antagonist preincubation.
Interestingly, the D2R antagonist was able to invert the effect observed in the BK+SUM-treated
cells. ROS production was higher (by 45%) compared with samples stimulated with BK+SUM
without the antagonists. The achieved values were also statistically significant (109% increase)
Cooperative action of bradykinin B2 receptor and dopamine D2 receptor in human endothelial cells
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compared with the sample treated with SUM after preincubation with eticlopride. HUV-EC-Cs
incubated with SUM did not show interesting changes, regardless of whether they were pretreated
with the antagonist or not. Prestimulation with apocynin significantly reduced ROS production
in the BK- and BK+SUM-treated cells.
Modulation of antioxidant enzymes in endothelial cells treated with BK
and SUM
The intracellular ROS concentration depends on the action of antioxidant systems. Among
others, antioxidant enzymes such as SOD and CAT play a decisive role in regulating the bal-
ance between ROS generation and decomposition. Several SOD isoforms regulate oxidative
processes–manganese-containing superoxide dismutase mainly in the mitochondria and
Fig 1. Endogenous expression of B2R and D2R in the HUV-EC-C cell line. (A) The B2R and D2R mRNA levels in cells were detected by RT-PCR. (B) The
endogenous expression of B2R and D2R proteins at cell membranes was analyzed by immunocytochemistry using specific antibodies for the extracellular domains of the
receptors. The cell nuclei were counterstained with DAPI (blue signal).
https://doi.org/10.1371/journal.pone.0206443.g001
Fig 2. ROS production by HUV-EC-Cs treated with B2R and D2R agonists. DCFH-DA-loaded endothelial cells
(1.0 × 105) were stimulated with 100 nM BK, 100 nM SUM, or both agonists simultaneously. Some samples were
additionally preincubated with 10 μM HOE 140 or 10 μM eticlopride for 30 minutes or 1 μM apocynin for 1 hour prior
to agonist stimulation. The bars represent the mean percentage of the changes in ROS production relative to the
untreated cells (with an assumed reference control value of 100%; dashed line). The more significant differences were
indicated inside figure. �P< 0.001 versus BK-treated cells, #P< 0.001 versus SUM-treated cells.
https://doi.org/10.1371/journal.pone.0206443.g002
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peroxisomes or copper- and zinc-containing superoxide dismutases, most abundant in the
cytoplasm [30]. In our current study, the SOD activity, measured by gel staining after native
PAGE, was normalized to the amount of sample protein. The representative gel in grayscale
presents the SOD isoforms in the studied samples–the upper band indicates MnSOD and the
lower band corresponds to Cu/ZnSOD (Fig 3A). Densitometric analysis of the gel bands
allowed a semiquantitative evaluation of the activity of the SOD isoforms (Fig 3B). Stimulation
with BK or SUM increased the MnSOD activity by 30% and 15%, respectively, whereas simul-
taneous treatment with both agonists yielded an opposite result, i.e. showing a slight but signif-
icant decrease by 13%. In the case of the Cu/ZnSOD isoform, greater activity was evident in
every sample in comparison to the control sample. The obtained values were higher by 27%,
38%, and 44%, respectively, for the BK, SUM, and BK+SUM stimulated cells.
Fig 3. Effect of B2R and D2R agonists on antioxidant enzyme activity. Endothelial cells (1 × 106) were treated with 100 nM BK, 100 nM SUM, or both agonists
simultaneously for 2 hours. In some samples, the cells were additionally preincubated with 10 μM HOE 140 or 10 μM eticlopride for 30 minutes prior to receptor agonist
stimulation. (A) The enzymatic activity of MnSOD and Cu/ZnSOD in cell lysates normalized to the amount of sample protein was measured after protein separation by
native PAGE. (B) The changes in MnSOD and Cu/ZnSOD activity calculated after densitometric gel analysis are presented relative to the untreated cells (with an
assumed reference control value of 100%; dashed line). (C) The enzymatic activity of CAT was spectrophotometrically measured and normalized to the amount of
sample protein. The figures indicate changes in the percentage of CAT activity relative to the untreated cells (with an assumed reference control value of 100%; dashed
line). The bars represent the mean values ± SD from at least three experiments performed in duplicate. �P< 0.001 versus BK-treated cells, #P< 0.001 versus SUM-
treated cells.
https://doi.org/10.1371/journal.pone.0206443.g003
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The other antioxidant enzyme investigated in this study was CAT, whose activity was assayed
by spectrophotometric monitoring of H2O2 decomposition and the obtained values were normal-
ized to the sample protein amount. An increase in CAT activity was observed after the treatment
with BK, SUM, and BK+SUM (by 107%, 34%, and 61% respectively, Fig 3C). However, the BK
+SUM-treated cells showed significantly lower CAT activity compared with the BK-treated and
SUM-treated cells. Similar experiments performed in cells that were additionally preincubated
with the antagonists showed interesting results. Preincubation with HOE 140 caused a diminution
of CAT activity in cells stimulated with BK and BK+SUM (by 70% and 50%, respectively), sug-
gesting specific involvement of B2R, while no changes were observed in the SUM-treated cells,
which showed a similar level of activity to the cells without prior exposure to HOE 140 (about a
30% increase). In turn, cell prestimulation with eticlopride produced no effect on the BK action,
showing similar CAT activity to that observed in the BK-sample without exposure to this antago-
nist (about 115%). In addition, eticlopride attenuated the enzyme activity in cells incubated with
SUM (by 12%). The most interesting observation was that the BK+SUM-treated cells preincu-
bated with eticloropide showed by 31% higher enzyme activity than in the corresponding sample
without the D2R antagonist. This effect was statistically significant compared with the samples
treated with BK+SUM with the BK/eticlopride-treated cells.
Influence of co-treatment with the B2R and D2R agonists on NOS3
activation and NO production in endothelial cells
Endothelial nitric oxide synthase is the principal enzyme regulating NO release by endothelial
cells. In our study, the activation of NOS3 was examined by measuring the ratio of protein
expression of NOS3 phosphorylated at Ser1177 to the total NOS3 protein. Stimulation with
BK and SUM at different incubation times was performed and the obtained images are shown
in Fig 4A. The pNOS3/NOS3 ratio was calculated after quantification of the corresponding
bands by densitometric analysis with Quantity One Software and the obtained values were
normalized to β-actin protein expression (Fig 4B). A significant increase in NOS3 phosphory-
lation was observed in every sample after 2-min stimulation. The highest value was obtained
for BK (1.73), followed by SUM (1.51) and BK+SUM (1.45). Longer cell stimulation (5 min)
caused a decrease in the pNOS3/NOS3 index in the BK-treated cells (1.14), whereas this value
in the SUM-treated sample was similar to that observed after 2 minutes (1.65). However, an
interesting effect was observed in the BK and SUM co-stimulated cells, in which a significant
increase in NOS3 phosphorylation was achieved, resulting in a pNOS3/NOS3 ratio of 2.32.
The analysis of NOS3 activation was supplemented by additional measurements of NO
release by endothelial cells. NO production was measured by assaying the nitrite concentration
in cell supernatants with a fluorometric technique with an assigned reference value of 100%
for untreated cells. The obtained results (Fig 4C) revealed time-dependent changes in NO
release after stimulation with the receptor agonists. The BK-treatment increased the NO con-
centration by 55% after 30 minutes, whereas longer incubation for 1 hour led to its decrease by
about 30%. The most remarkable observations were made in the BK+SUM samples, in which
30-min stimulation caused a significant increase in the NO concentration (by 80%) and longer
incubation increased it even by 131%. The SUM-treated cells also showed enhanced NO
release (by 80% and 100% for 30-min and 60-min incubation, respectively).
Inflammatory response of endothelial cells induced by the B2R and D2R
agonists
Cell responses that are dependent on oxidative stress processes are associated with the produc-
tion of a variety of proinflammatory factors. We here analyzed the role of the B2R and D2R
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agonists in regulating the release of IL-6, i.e. one of the first cytokines appearing during inflam-
matory response. Cells without TNF-α pretreatment did not show any significant changes in
IL-6 production after the receptor agonist treatment (Fig 5A). In turn, an increase in IL-6
release was registered in the TNF-α-stimulated cells after incubation with BK (by 34%),
whereas a weak decrease was observed in the SUM-treated cells (Fig 5B). However, the simul-
taneous stimulation with BK and SUM led to the total abolition of the BK-induced effect,
showing even a significant decrease in IL-6 release compared to the untreated cells (by 18%).
To confirm the effects of the receptor agonists, experiments were also performed in cells pre-
treated with specific antagonists. The use of HOE 140 reversed the achieved effect on IL-6 pro-
duction in the BK- and BK+SUM-treated cells and had no influence on the SUM-stimulated
cells. In the latter sample, the IL-6 concentration was comparable to the value observed in the
untreated cells (Fig 5C). In turn, eticlopride effectively inhibited the effect observed in cells
treated with BK+SUM, whereas no changes were produced by this antagonist in the BK- or
SUM-stimulated cells (Fig 5D). In the case of the BK+SUM sample, a significant increase in
Fig 4. NOS3 activation and NO production by endothelial cells treated with B2R and D2R agonists. Confluent cells were stimulated with 100 nM BK, 100 nM SUM,
or both agonists simultaneously for the indicated times. (A) The protein expression levels of pNOS3 Ser1177 and NOS3 were analyzed by western blotting and
normalized to the amount of β-actin. (B) The pNOS3/NOS3 ratio was quantified by densitometric analysis. The bars represent the mean values ± SD from three
independent experiments as compared to the untreated cells, assumed to have a ratio equal to 1 (dashed line). (C) The percentage of changes in NO production is
presented in comparison to the untreated cells, with an assumed reference control value of 100% (dashed line). The mean values ± SD from at least three experiments
performed in duplicate are shown. �P< 0.001 versus BK-treated cells, #P< 0.001 versus SUM-treated cells.
https://doi.org/10.1371/journal.pone.0206443.g004
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IL-6 production was observed (by 13%, relative to cells treated only with eticlopride). It should
also be noted that used receptor antagonists did not have any significant influence on the cyto-
kine release by endothelial cells. The IL-6 concentration was unaffected in the untreated cells
regardless of any preincubation with HOE 140 or eticlopride (1442.6 pg/mg of protein).
Influence of BK and SUM on the expression of pro- and anti-apoptotic
proteins in endothelial cells
An impaired oxidant-antioxidant balance and enhanced inflammatory responses can lead to
the development of apoptotic processes. We examined the effect of BK and SUM on the
expression of the pro-apoptotic protein Bax and the anti-apoptotic proteins Bcl-2 and Bcl-xL
Fig 5. IL-6 release by endothelial cells stimulated with B2R and D2R agonists. Confluent cells, (A) preincubated or (B) non-preincubated with 10 ng/ml TNF-α for
24 hours, were stimulated with 100 nM BK, 100 nM SUM, or both agonists simultaneously for 6 hours. Some samples were additionally pretreated with (C) 10 μM HOE
140 or (D) 10 μM eticlopride for 30 minutes prior to receptor agonist induction. The protein production of IL-6 in the culture medium was analyzed by ELISA and
normalized to the amount of sample protein. The bars present the mean values ± SD from at least three experiments in triplicate. &P< 0.001 versus untreated cells,
�P< 0.001 versus BK-treated cells, #P< 0.001 versus SUM-treated cells.
https://doi.org/10.1371/journal.pone.0206443.g005
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by western blotting. The detected bands for these proteins indicated significant changes in
their expression in endothelial cells (Fig 6A). The Bcl-2/Bax (Fig 6B) and Bcl-xL/Bax (Fig 6C)
ratios were calculated by densitometric analysis of the corresponding bands normalized to the
β-actin protein content. The ratio values were compared to that for untreated cells, which were
given a reference value of 1. Both Bcl-2/Bax and Bcl-xL/Bax ratios showed a similar effect
depending of the incubation time, presenting an insignificant decrease in cells stimulated with
BK for 6 hours (0.68 and 0.77, respectively). In contrast, cells incubated with SUM and with
BK+SUM showed higher values of both indexes compared to the untreated cells. The Bcl-2/
Bax ratio increased to 1.33 and 1.56 in the SUM- and BK+SUM-treated cells, respectively. In
the case of the Bcl-xL/Bax ratio, the values increased by 0.39 and 0.66, accordingly. Extended
stimulation caused an increasing tendency toward an anti-apoptotic response only in cells
treated with both agonists. After 24 hours, the calculated Bcl-2/Bax and Bcl-xL/Bax indexes
were 1.96 and 2.11, respectively. Moreover, no significant changes were observed in cells stim-
ulated with BK or SUM alone during a 24-hour period, as the ratio values were comparable to
those in the untreated samples.
Fig 6. Effect of B2R and D2R agonists on the expression of pro- and anti-apoptotic proteins. Cells (1.0 × 106) were treated with 100 nM BK, 100 nM SUM, or both
agonists simultaneously for 6 or 24 hours. (A) The protein expression levels of Bcl-2, Bcl-xL, and Bax was analyzed by western blotting. The (B) Bcl-2/Bax and (C) Bcl-
xL/Bax ratios were calculated by densitometric analysis and the values were normalized to the β-actin expression level. The figures represent the mean values ± SD from
two experiments, compared with the value obtained for the untreated cells, assumed to be 1 (dashed line). &P< 0.001 versus untreated cells, � P< 0.001 versus BK-
treated cells, #P< 0.005 versus SUM-treated cells.
https://doi.org/10.1371/journal.pone.0206443.g006
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Caspase 3/7 activity in endothelial cells treated with B2R and D2R agonists
Changes in the expression of Bax, Bcl-2, and Bcl-xL proteins are commonly associated with
the modulation of the caspase cascade. We thus assessed the influence of the B2R and D2R
agonists on the caspase activity, which is induced by pro-apoptotic stimuli. Cells treated with
BK, SUM, or both agonists simultaneously showed no significant changes in caspase 3/7 activ-
ity (Fig 7A). Nonetheless, cells preincubated with the proinflammatory cytokine TNF-α dem-
onstrated an interesting profile of caspase activity under the treatment with the receptor
agonists (Fig 7B). Increased enzyme activity was observed in the samples treated with BK
alone (by 20%), but was significantly reduced by 22% after exposure to both BK and SUM,
with no significant differences in the cells stimulated with SUM alone.
Endothelin-1 release by endothelial cells by the B2R and D2R agonists
Endothelin-1, i.e. an endothelium-derived vasoactive peptide, is involved in promotion of
cytokine and ROS generation [5]. In our study, a slight but significant increase in ET-1 release
was registered in cells stimulated with BK (by 11%), whereas a weak decrease was observed in
the SUM-treated cells. On the other hand, the simultaneous stimulation with BK and SUM led
to the total abolition of the effect exerted by the BK treatment (Fig 8A), finally with even a sig-
nificant decrease in ET-1 release (by 24% compared to untreated cells). Moreover, endothelial
cells preincubated with TNF-α showed stronger changes in the ET-1 profile after the treatment
with the receptor agonists. In samples treated only with BK, the ET-1 release was significantly
increased (by 68%), while cells treated with SUM or simultaneously with BK and SUM showed
reduced ET-1 production in comparison to the control samples (by 50% and 28%,
respectively).
Discussion
Numerous studies to date have confirmed that endothelial dysfunctions are a hallmark of a
wide range of cardiovascular diseases, such as atherosclerosis and hypertension, which are also
associated with oxidative stress and an inflammatory state [31]. Based on our prior study,
Fig 7. Relative caspase 3/7 activity in endothelial cells after treatment with B2R and D2R agonists. Cells (1.0 × 104) without (A) preincubation or (B) preincubated
with 10 ng/ml TNF-α for 6 hours were treated with 100 nM BK, 100 nM SUM, or both agonists simultaneously for 24 hours. Enzyme activity was analyzed with a
chemiluminescent assay. The figures present the mean values ± SD of the percentage change in caspase 3/7 activity compared with the untreated cells (with an assumed
reference control value of 100%; dashed line). The results were obtained from at least three experiments performed in triplicate. &P< 0.001 versus untreated cells,
�P< 0.001 versus BK-treated cells, #P< 0.001 versus SUM-treated cells.
https://doi.org/10.1371/journal.pone.0206443.g007
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which demonstrated an interaction between these two receptors with alterations of their sig-
naling pathways [22], it could be speculated that such interaction would modify any agonist-
induced effects on endothelial functions. Taking into consideration that a high BK concentra-
tion in the blood may develop inflammatory processes in the vascular system [5–6], the goal of
our current study was to define a possible role of the cooperation between B2 and D2 receptors
in regulating processes related to oxidative stress, inflammation, and apoptosis in endothelial
cells. These studies seem to be interesting, especially taking into account previous reports indi-
cating anti-oxidative effects exerted by D2R activation [14]. In accordance with the convincing
evidence to date that B2R and D2R are endogenously expressed in primary endothelial cells
isolated from the umbilical vein [18, 32], we have confirmed here that these proteins are abun-
dantly expressed in the endothelial cell line used in this study (Fig 1).
The imbalance between the production and decomposition of ROS, which normally act as
secondary cellular messengers, leads to the state known as oxidative stress. In the present
study, BK-induced ROS overproduction was detected and found to be nearly completely
inhibited by HOE 140 (Fig 2), indicating that this effect was mainly related to B2R activation.
In contrast, the eticlopride pretreatment had no impact on the BK-induced response. Unlike
our present observations, previous reports have suggested a protective action of BK against
ROS production in endothelial cells [8, 33]. It should be pointed out, however, that endothelial
cells were treated with a BK concentration near to the physiological level in those studies,
whereas we used a higher dose and additional supplementation with kininase inhibitors to
avoid rapid BK degradation [28]. On the other hand, some studies using BK at concentrations
of 1–10 μM reported enhanced production of several reactive oxygen species in different endo-
thelial cells via the NADPH oxidase-dependent pathway [10–12]. Consequently, our results
have confirmed that the BK-induced effect in the HUV-EC-C cell line may provide a patholog-
ical endothelial cellular model. The most relevant observations from the present analyses were
related to the fact that the cell stimulation with the D2R agonist did not alter the basal ROS
level, whereas co-stimulation with BK and SUM significantly diminished the BK-induced
effect on ROS production. Furthermore, eticlopride reversed this effect, suggesting that it
occurs via a direct role of D2R, changing the B2R signaling. Hence, we demonstrate here that
Fig 8. Endothelin-1 release by endothelial cells stimulated with B2R and D2R agonists. Confluent cell cultures were
preincubated with 10 ng/ml TNF-α for 6 hours, followed by stimulation with 100 nM BK, 100 nM SUM, or both
agonists simultaneously for 24 hours and the ET-1 concentration was measured by ELISA. The bars present the mean
values ± SD of the percentage change in endothelin-1 production compared with the untreated cells (with an assumed
reference control value of 100%; dashed line). The results were obtained from at least three experiments performed in
duplicate. &P< 0.001 versus untreated cells, �P< 0.001 versus BK-treated cells, #P< 0.001 versus SUM-treated cells.
https://doi.org/10.1371/journal.pone.0206443.g008
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the selective D2R agonist sumanirole can counteract the pathological effects induced by BK.
Moreover, apocynin abolished the effects exerted by the receptor agonists, indicating the
exclusive role of NADPH oxidase in these responses. This enzyme is considered to be the pre-
dominant source of ROS in the endothelium [12].
The intracellular ROS concentration depends not only on their production but also on
their subsequent metabolism by antioxidant enzymes, such as SOD and CAT. SOD is the prin-
cipal defense against superoxide radicals in cells by catalyzing their dismutation to oxygen and
hydrogen peroxide. Since we demonstrated the regulation of ROS production by the B2R and
D2R agonists, we subsequently investigated whether the agonists could also modulate the
activity of antioxidant enzymes. The role of BK in the upregulation of SOD activity was indi-
cated previously in cardiomyocytes pretreated with H2O2 as well as in vivo in hyperglycemic
rats [9, 34]. It was also demonstrated that D2R agonists, such as ropinirole and bromocriptine,
similarly cause up-regulation of SOD activity in mice striatum and cardiomyocytes [16, 35]. In
accordance with these observations, our current study also showed the induction of both SOD
isoforms in endothelial cells under the action of BK and SUM. Surprisingly, the co-stimulation
with both agonists gave unexpected results (Fig 3B), showing a significant decrease in MnSOD
activity in comparison to the Cu/ZnSOD isoforms. This difference between SOD isoform
activities was quite interesting because the half-life of MnSOD is relatively long, compared to
the mainly cytosolic Cu/ZnSOD [36]. However, we observed reduced ROS release in response
to the co-stimulation with BK and SUM, which correlates with the declining MnSOD activity,
suggesting a significantly lower demand for this enzyme under these conditions. Another
alternative explanation may be related to intensive use of this enzyme in the destruction of
superoxide radicals, which leads to a decrease in SOD concentration and consequently in
enzyme activity. Therefore, taking into account the fact that the production of superoxide
occurs primarily in mitochondria [5], the observed low activity of MnSOD after the co-treat-
ment with both agonists may be attributed to the antioxidative effect caused by the B2R-D2R
interaction.
As mentioned previously, the action of SOD leads to an enhanced production of another
component of ROS, hydrogen peroxide. Cells are protected from the negative effects of H2O2
by CAT, which rapidly decomposes H2O2 to water and oxygen [30]. In this study, we demon-
strated a significant BK-induced increase in CAT activity, an effect that was partially inhibited
by HOE 140, confirming the participation of B2R (Fig 3C). A previous report also showed the
participation of BK in CAT induction [34]. Thus, we suggest that B2R activation in endothelial
cells leads to rapid ROS release, including superoxide radicals and hydrogen peroxide, which
are scavenged by SOD and CAT to maintain the balance between pro- and antioxidative sys-
tems. On the other hand, the role of ropinirole, i.e. a D2R agonist, in CAT activation to regu-
late oxidative stress was previously confirmed in the mouse striatum [16]. We did not observe
significant changes in CAT activity after the cell incubation with SUM. Nevertheless, the effect
resulting from the BK+SUM stimulation in our study was noteworthy. Simultaneous treat-
ment with both agonists showed a strong decrease in the BK-induced CAT activity, which was
reversed by the cell preincubation with eticlopride. These observations suggest a cooperative
action of B2R and D2R in the regulation of oxidative stress in endothelial cells. Interestingly,
the BK+SUM effects on CAT activity in endothelial cells correlated with ROS production (Fig
2). Similar as in the case of decreased SOD activity we can assume that the impaired CAT
activity may be attributed to a lower demand of the enzyme because the production of ROS is
diminished. Ultimately, our findings suggest that the cooperation between B2R and D2R not
only downregulates ROS production in endothelial cells but also alters antioxidant systems,
responsible for the maintenance of the balance between pro- and antioxidative processes.
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Nitric oxide is a pivotal regulator of endothelial functions, e.g. vascular tone. In endothelial
cells, NO is produced by the NOS3 isoform after its activation by intracellular Ca2+ ions and
phosphorylation at Ser1177 [37]. Reduced NO production is mostly associated with cardiovas-
cular diseases [38]. One of the main causes of altered NO release by cells is the inhibition of
NOS3 phosphorylation. Our results (Fig 4B) are in accord with a previous study on endothelial
cells, in which stimulation with 1 μM BK led to a rapid induction of NOS3 phosphorylation
[39]. However, after 5-min incubation, this effect was attenuated. Based on the fact that SUM
produced only a weak increase, irrespective of the incubation time, the strong NOS3 activation
observed in cells stimulated with BK + SUM after 5 minutes can be attributed mainly to a
cooperation between the B2R and D2R receptors. It is possible that these receptors compete
for G proteins, resulting in modified receptor signaling. B2R regulates calmodulin binding to
NOS3 in a Ca2+-dependent manner, causing enzyme activation and NO production, whereas
D2R can activate NOS3 via a cAMP-dependent pathway [37, 40]. Hence, signaling changes
induced during endothelial cell co-stimulation with BK and SUM cannot be excluded. Indeed,
during late D2R signaling, a different cAMP-independent pathway for Akt activation is also
proposed [41], which is required for NOS3 phosphorylation [37]. Therefore, additional
detailed studies on B2R and D2R signaling are desirable.
The measurements of nitrite, i.e. one of terminal NO metabolites, were consistent with the
observed NOS3 phosphorylation levels. A transient rise in the NO release by BK was observed,
with the highest peak seen after 30 minutes (Fig 4C). Similar results were previously obtained
by Cokić and co-workers, who reported a quick and transient endothelial cell response pattern
that is dependent on the NO induced strictly by B2R activation [42]. On the contrary, the D2R
involvement in the regulation of NO production has not been well studied. Thus far, there has
been some evidence indicating a specific role of this receptor in inducing NOS3 expression in
vascular smooth muscle and endothelial cells but NO release was not measured [40]. We here
report for the first time the involvement of D2R not only in NOS3 phosphorylation but also in
NO production by endothelial cells. Interestingly, in comparison to BK, the SUM-dependent
response was consistent and longer, as the BK-induced effect was strongly reduced after
1-hour incubation. Simultaneous treatment of HUV-EC-Cs with both agonists led to a grow-
ing increase in nitric oxide production, which depended on the incubation time. It should be
noted that these effects correlate with the measured levels of NOS3 activation. These findings
confirm that D2R agonists can regulate BK activities through the modulation of cellular func-
tions dependent on NO production. It is worth mentioning that increased NO scavenging by
ROS has been associated with reduced NO bioavailability and, therefore, with impaired endo-
thelium functionality, including the development of oxidative stress [5]. Hence, augmented
NO production by BK+SUM-treated cells may prevent the early development of oxidative
stress. However, it should be noted that NO production sometimes can lead to an increased
production of peroxynitrite radicals, especially when antioxidant systems do not work
properly.
Several studies affirm that many proinflammatory cytokines are triggered by oxidative
stress, especially by mitochondrial ROS [31]. Increased release of intracellular ROS leads to the
stimulation of an important proinflammatory factor NF-κB, which plays a pivotal role in the
induction of cytokine expression, particularly IL-6 [43]. We did not observe any significant
effect on IL-6 production following the endothelial cell stimulation with the B2R or D2R ago-
nists. However, the preincubation of HUV-EC-Cs with TNF-α, which to some extent reflects a
model of inflamed cells, allowed detection of significant changes in cytokine release (Fig 5). In
brief, SUM was incapable of prompt IL-6 production, whereas the BK-induced cytokine
release was blocked when the cells were co-incubated with both agonists. The use of the recep-
tor antagonists confirmed the mediation of B2R and D2R in the observed effects. These results
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agree with a previous report on the regulation of IL-6 production by BK [44]. Nevertheless,
our study provides new observations regarding the D2R-mediated regulation of the inflamma-
tory response induced by BK. In fact, the anti-inflammatory effects of D2R were described in a
recent report [45] showing reduced expression of the NF-κB protein in a mouse experimental
model of intracerebral hemorrhage. In total, it seems that the high degree of NOS3 phosphory-
lation after the BK+SUM stimulation with subsequent enhanced NO release could be helpful
in the diminution of the IL-6 concentration in the cell culture medium, especially considering
a previous report demonstrating that a higher cytokine concentration correlates with the inhi-
bition of NOS3 phosphorylation at Ser1177 [46].
Cell apoptosis can be initiated by several mechanisms, including intrinsic signals such as
oxidative stress. The sensitivity of cells to apoptotic stimuli depends on the balance between
anti-apoptotic (e.g. Bcl-2 and Bcl-xL) and pro-apoptotic proteins (e.g. Bax). The interactions
between these two groups of proteins determine the initiation of the caspase cascade, including
caspase 3, an important effector molecule in apoptosis [47]. Taking this into account, we inves-
tigated whether the cooperation between B2R and D2R may result in the regulation of apopto-
tic processes in endothelial cells. A decisive pro-apoptotic effect of BK has not been
demonstrated. However, Oeseburg and co-workers reported attenuation of H2O2-induced
apoptosis in bovine aortic endothelial cells under the action of BK at a physiological concentra-
tion [33]. Similar results were obtained in other studies performed in pig cerebral microvascu-
lar endothelial cells stimulated with H2O2 or lipopolysaccharide and in serum-deprived
HUVEC cells [48–49]. This study has revealed a weak pro-apoptotic effect induced by BK at a
pathological concentration in endothelial cells (Fig 6). The ratio of anti- to pro-apoptotic pro-
teins decreased after 6-h incubation, whereas longer incubation with BK did not exert any
notable effect. Based on these results, we could not conclude that BK promotes or attenuates
apoptosis, especially as no changes were observed in caspase 3/7 activity in the BK-treated cells
(Fig 7A). It seems therefore that this peptide alone is not able to induce apoptotic pathways in
the endothelium. However, when the cells were additionally pretreated with the proinflamma-
tory cytokine TNF-α, a weak but significant increase in caspase 3/7 activity was induced (Fig
7B). Interestingly, a similar result was observed during our analysis of IL-6 production (Fig 5),
confirming that, upon stress and proinflammatory stimuli, high doses of BK can potentiate
not only endothelium dysfunctions but also pro-apoptotic effects. On the other hand, our find-
ings indicate a slight increase in the anti-apoptotic ratio after 6-h incubation with SUM (Fig
6A, 6B and 6C). Different reports provide evidence showing the participation of bromocrip-
tine, i.e. a D2R agonist, in the down-regulation of caspase 3 activity and the induction of Bcl-2
protein expression in rat cardiomyocytes after myocardial ischemia [35, 50]. Moreover, Nair
and co-workers [51] showed the inhibition of H2O2-induced apoptotic processes by bromo-
criptine in nigral dopamine and PC-12 cell lines. However, our study showed that caspase 3/7
activity was unchanged, indicating no anti-apoptotic effects of the D2R action (Fig 7). These
results suggest that SUM alone plays no significant role in the control of apoptosis in endothe-
lial cells. This clear discrepancy with previous reports may be related to the specificity of the
D2R agonists in these studies. Bromocriptine possesses a higher binding affinity for dopamine
receptor type 3 than for D2R, whilst SUM is a highly selective agonist for D2R [29]. Neverthe-
less, the surprising results obtained when the cells were treated simultaneously with both ago-
nists argue for an anti-apoptotic role of D2R. The level of pro-apoptotic proteins (Fig 6) as well
as the activity of caspase 3/7 in the TNF-α–pretreated endothelial cells after stimulation with
both BK and SUM was significantly reduced (Fig 7B). These results strongly indicate a protec-
tive effect on endothelial cells exerted by the cooperation of B2R and D2R, which also prevents
the development of apoptosis. The anti-apoptotic action of the B2R/D2R agonists may also be
related to the pNOS3-dependent pathway and NO production. The inhibition of apoptosis by
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NO in different cell types, including endothelial cells, has been demonstrated [47]. Moreover,
the prevention of apoptosis has been reported to correlate mainly with a reduced calcium over-
load [35], and we recently reported the abolition of BK-induced calcium release in HEK293
cells treated simultaneously with B2R and D2R agonists [22]. Nevertheless, our studies were
performed in cellular model of endothelium, in which the observed changes in apoptotic indi-
cators no necessarily may lead to apoptosis. To obtain a more reliable response about BK and
SUM action in apoptosis it is necessary to introduce a more sophisticated model, for example
in vivo studies.
On the other hand, secretion of endothelin-1, a vasoactive peptide involved in the patho-
physiology of many cardiovascular diseases such as hypertension, atherosclerosis, and hyper-
cholesterolemia, is dependent on the intracellular calcium concentration [52]. Increased ET-1
concentration in blood is a positive indicator of endothelium dysfunction. Previous reports
have indicated BK mediation in the induction of ET-1 release [52–53]. Our study provides
results that confirm this observation (Fig 8) and, in addition, reports for a first time a protec-
tive role of the D2R agonist in the regression of the BK-dependent production of endothelin-1.
Fig 9. Involvement of B2R and D2R in oxidative and inflammatory responses as well as in apoptotic processes in
endothelial cells. BK–bradykinin, B2R –bradykinin B2 receptor, CAT–catalase, D2R- dopamine D2 receptor, ET-1 –
endothelin-1, IL-6 –interleukin-6, MnSOD–mitochondrial superoxide dismutase, pNOS3 –phosphorylated endothelial
nitric oxide synthase, ROS–reactive oxygen species, SUM–sumanirole. Thick arrows represent mechanisms that may
not necessarily occur directly and in which additional factors may be involved.
https://doi.org/10.1371/journal.pone.0206443.g009
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Therefore, the effect of SUM on the regulation of endothelial cell dysfunction induced by BK con-
firms our hypothesis that both receptors may interact and regulate cellular function. We suppose
that the conformational changes of receptors’ structure after dimerization may hinder or facilitate
the access to one of the agonists or maybe the receptors compete with each other to the appropri-
ate G protein. Of course, we cannot exclude that other GPCRs, which can also dimerize with B2R
and/or D2R, or can at least partly contribute to the observed effects. However additional studies
including analysis in vivo or ex vivo could provide more reliable information.
In conclusion, our data indicate a significant role of D2R in the regulation of the effects
induced by a B2R agonist on oxidative stress, and on inflammatory as well as apoptotic pro-
cesses in endothelial cells (Fig 9). These changes seem to be associated with the cooperation
between these receptors, possibly during direct interactions at the cell membrane, which can
modify their typical signaling pathways. Taking into consideration that the imbalance of the
aforementioned processes leads to endothelial dysfunction, its regulation could probably pro-
tect or even reverse vascular pathologies. Thus, the findings presented herein enrich the exist-
ing knowledge of the complex functioning of the endothelium, which may open up new
perspectives in the search for modulators of B2 and D2 receptors to develop new drug candi-
dates with potential therapeutic applications in the treatment of cardiovascular disorders.
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